IGC's Alzheimer's disease cannabinoid-based treatment has a 15-point increase in chances of progressing to the next stage


After Phase I, India Globalization Capital's Alzheimer's disease cannabinoid-based treatment has a 15-point increase in chances of progressing to the next stage.

After completing its Phase I study, India Globalization Capital's IGC-AD1 for Alzheimer's disease (AD) symptoms saw its Phase Transition Success Rate (PTSR) jump 15 points to 73 percent.

The primary aim of the multiple ascending dosage Phase I trial (NCT04749563) is safety, with improvements in the Neuropsychiatric Inventory (NPI) scale as a secondary efficacy outcome. IGC-AD1, which is based on the psychoactive component of cannabis, THC, is intended to help individuals with Alzheimer's disease enhance their quality of life.

Phase I completion also resulted in a 2-point increase in the drug's Likelihood of Approval (LoA), which now stands at 9%. GlobalData's analysis uses a combination of machine learning and its proprietary technology to identify LoA. It's computed by multiplying the PTSR by the number of stages the medicine has still to complete. A drug's LoA and PTSR can be determined by taking into account factors such as therapy area, indication, and molecule type.

IGC has a market capitalization of $67.6 million dollars.